[1]
Papas T. Management of peripheral arterial disease after menopause. Curr Vasc Pharmacol 2023. Epub ahead of print
[2]
Anagnostis P, Mikhailidis DP, Blinc A, et al. The effect of menopause and menopausal hormone therapy on the risk of peripheral artery disease. Curr Vasc Pharmacol 2023; 21(5): 293-6.
[http://dx.doi.org/10.2174/0115701611263345230919122907] [PMID: 37779405]
[http://dx.doi.org/10.2174/0115701611263345230919122907] [PMID: 37779405]
[3]
Poredoš P, Schernthaner GH, Blinc A, et al. Endocrine disorders and peripheral arterial disease: A Series of Reviews. Curr Vasc Pharmacol 2023; 21(3): 147-8.
[http://dx.doi.org/10.2174/1570161121666230516141319] [PMID: 37194233]
[http://dx.doi.org/10.2174/1570161121666230516141319] [PMID: 37194233]
[4]
Anagnostis P, Bitzer J, Cano A, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas 2020; 135: 82-8.
[http://dx.doi.org/10.1016/j.maturitas.2020.03.007] [PMID: 32209279]
[http://dx.doi.org/10.1016/j.maturitas.2020.03.007] [PMID: 32209279]
[5]
Leal LG, Lopes MA, Batista ML Jr. Physical exercise-induced myokines and muscle-adipose tissue crosstalk: A review of current knowledge and the implications for health and metabolic diseases. Front Physiol 2018; 9: 1307.
[http://dx.doi.org/10.3389/fphys.2018.01307] [PMID: 30319436]
[http://dx.doi.org/10.3389/fphys.2018.01307] [PMID: 30319436]
[6]
Studen KB, Gaberscek S, Zaletel K, et al. Thyroid disorders and peripheral arterial disease. Curr Vasc Pharmacol 2023;. 21
[http://dx.doi.org/10.2174/0115701611271284231105063148] [PMID: 37957913]
[http://dx.doi.org/10.2174/0115701611271284231105063148] [PMID: 37957913]
[7]
R H, A J , Dp M , et al. Growth hormone, atherosclerosis and peripheral arterial disease: Exploring the spectrum from acromegaly to growth hormone deficiency. Curr Vasc Pharmacol 2023. 21
[http://dx.doi.org/10.2174/0115701611269162231106042956] [PMID: 37962050]
[http://dx.doi.org/10.2174/0115701611269162231106042956] [PMID: 37962050]